Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034861222> ?p ?o ?g. }
- W2034861222 endingPage "255" @default.
- W2034861222 startingPage "249" @default.
- W2034861222 abstract "We investigated the activity and toxicity of a combination of vinorelbine 25 mg/m2 on days 1 and 15; epirubicin 25 mg/m2 on days 1, 8, 15; and 5-fluorouracil continuous infusion at 200 mg/m2 every day, administered as first-line chemotherapy in anthracycline-naive metastatic breast cancer patients. Fifty-three patients entered the study. Cycles were repeated every 28 days. Objective response was 60% by World Health Organisation (WHO) criteria and 63% by Response Evaluation Criteria in Solid Tumours (RECIST). The median time to progression was 12.7 months (17.6 months in responders) and the median survival duration was 32.9 months. The dose-limiting toxicity was leucopenia (grade 3/4 in 36% of patients). Grade 3/4 non-haematological toxicities included mucositis in 11% of patients, skin and cardiac toxicity in 4% and 2%, respectively. The combination of vinorelbine, epirubicin and 5-fluorouracil continuous infusion was found to be an active and manageable first-line regimen for metastatic breast cancer patients." @default.
- W2034861222 created "2016-06-24" @default.
- W2034861222 creator A5007488646 @default.
- W2034861222 creator A5010146228 @default.
- W2034861222 creator A5010499606 @default.
- W2034861222 creator A5011597193 @default.
- W2034861222 creator A5016082554 @default.
- W2034861222 creator A5019107001 @default.
- W2034861222 creator A5020736353 @default.
- W2034861222 creator A5022648629 @default.
- W2034861222 creator A5022660275 @default.
- W2034861222 creator A5029949952 @default.
- W2034861222 creator A5036019590 @default.
- W2034861222 creator A5050426287 @default.
- W2034861222 creator A5065176823 @default.
- W2034861222 creator A5073879276 @default.
- W2034861222 creator A5077674568 @default.
- W2034861222 creator A5078266967 @default.
- W2034861222 creator A5090449542 @default.
- W2034861222 date "2005-01-01" @default.
- W2034861222 modified "2023-09-26" @default.
- W2034861222 title "Combination regimen of epirubicin, vinorelbine and 5-fluorouracil continuous infusion as first-line chemotherapy in anthracycline-naïve metastatic breast cancer patients" @default.
- W2034861222 cites W1755746957 @default.
- W2034861222 cites W1783154753 @default.
- W2034861222 cites W1923449517 @default.
- W2034861222 cites W1976440095 @default.
- W2034861222 cites W1998091677 @default.
- W2034861222 cites W2001630614 @default.
- W2034861222 cites W2013019516 @default.
- W2034861222 cites W2022210973 @default.
- W2034861222 cites W2029409133 @default.
- W2034861222 cites W2033416626 @default.
- W2034861222 cites W2048553013 @default.
- W2034861222 cites W2060029165 @default.
- W2034861222 cites W2071205059 @default.
- W2034861222 cites W2083279474 @default.
- W2034861222 cites W2085044126 @default.
- W2034861222 cites W2107577958 @default.
- W2034861222 cites W2117194901 @default.
- W2034861222 cites W2139248078 @default.
- W2034861222 cites W2141456559 @default.
- W2034861222 cites W2164203329 @default.
- W2034861222 cites W2167805334 @default.
- W2034861222 cites W2169073956 @default.
- W2034861222 cites W2183288147 @default.
- W2034861222 cites W2229497644 @default.
- W2034861222 cites W2231508224 @default.
- W2034861222 cites W2271753451 @default.
- W2034861222 cites W2271804810 @default.
- W2034861222 cites W2325015062 @default.
- W2034861222 cites W2416997884 @default.
- W2034861222 doi "https://doi.org/10.1016/j.ejca.2004.07.003" @default.
- W2034861222 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15661550" @default.
- W2034861222 hasPublicationYear "2005" @default.
- W2034861222 type Work @default.
- W2034861222 sameAs 2034861222 @default.
- W2034861222 citedByCount "8" @default.
- W2034861222 countsByYear W20348612222012 @default.
- W2034861222 countsByYear W20348612222023 @default.
- W2034861222 crossrefType "journal-article" @default.
- W2034861222 hasAuthorship W2034861222A5007488646 @default.
- W2034861222 hasAuthorship W2034861222A5010146228 @default.
- W2034861222 hasAuthorship W2034861222A5010499606 @default.
- W2034861222 hasAuthorship W2034861222A5011597193 @default.
- W2034861222 hasAuthorship W2034861222A5016082554 @default.
- W2034861222 hasAuthorship W2034861222A5019107001 @default.
- W2034861222 hasAuthorship W2034861222A5020736353 @default.
- W2034861222 hasAuthorship W2034861222A5022648629 @default.
- W2034861222 hasAuthorship W2034861222A5022660275 @default.
- W2034861222 hasAuthorship W2034861222A5029949952 @default.
- W2034861222 hasAuthorship W2034861222A5036019590 @default.
- W2034861222 hasAuthorship W2034861222A5050426287 @default.
- W2034861222 hasAuthorship W2034861222A5065176823 @default.
- W2034861222 hasAuthorship W2034861222A5073879276 @default.
- W2034861222 hasAuthorship W2034861222A5077674568 @default.
- W2034861222 hasAuthorship W2034861222A5078266967 @default.
- W2034861222 hasAuthorship W2034861222A5090449542 @default.
- W2034861222 hasConcept C121608353 @default.
- W2034861222 hasConcept C126322002 @default.
- W2034861222 hasConcept C141071460 @default.
- W2034861222 hasConcept C143998085 @default.
- W2034861222 hasConcept C2775930923 @default.
- W2034861222 hasConcept C2776694085 @default.
- W2034861222 hasConcept C2776802502 @default.
- W2034861222 hasConcept C2778239845 @default.
- W2034861222 hasConcept C2778496288 @default.
- W2034861222 hasConcept C2780350996 @default.
- W2034861222 hasConcept C2780456651 @default.
- W2034861222 hasConcept C2780835546 @default.
- W2034861222 hasConcept C2781413609 @default.
- W2034861222 hasConcept C29730261 @default.
- W2034861222 hasConcept C530470458 @default.
- W2034861222 hasConcept C71924100 @default.
- W2034861222 hasConcept C90924648 @default.
- W2034861222 hasConceptScore W2034861222C121608353 @default.
- W2034861222 hasConceptScore W2034861222C126322002 @default.
- W2034861222 hasConceptScore W2034861222C141071460 @default.
- W2034861222 hasConceptScore W2034861222C143998085 @default.